Cover
Cover | Jan. 09, 2023 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by Eagle Pharmaceuticals, Inc., or the Company, on January 9, 2022, or the Original Form 8-K. The Original Form 8-K furnished the Company's presentation, or the Original Presentation, of its business, products and product candidates, which the Company will use at its previously announced presentation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, being held January 9-12, 2023, and from time to time in meetings with investors. On January 10, 2023, the Company reissued the presentation, or the Updated Presentation, to correct certain figures reflected in the reconciliation tables included on slide 14 of the Original Presentation due to administrative errors. The other information disclosed in the Original Presentation and Original Form 8-K is unchanged. |
Document Period End Date | Jan. 09, 2023 |
Entity File Number | 001-36306 |
Entity Registrant Name | Eagle Pharmaceuticals, Inc. |
Entity Central Index Key | 0000827871 |
Entity Tax Identification Number | 20-8179278 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 50 Tice Boulevard |
Entity Address, Address Line Two | Suite 315 |
Entity Address, City or Town | Woodcliff Lake |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07677 |
City Area Code | 201 |
Local Phone Number | 326-5300 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock (par value $0.001 per share) |
Trading Symbol | EGRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |